Pathophysiology of Diethylstilbestrol Changes
Diethylstilbestrol (DES) and other related nonsteroidal estrogenic substances, e.g., dienestrol and hexestrol, were commonly prescribed for treatment of threatened abortion, toxemia, diabetes, and other pregnancy complications between the 1940s and 1960s. Although the effectiveness of these compounds has never been documented, their use continued until the discovery in 1971 of a link between a clear cell adenocarcinoma of the cervix and vagina and the use of these drugs.1 The impact of this discovery was much wider than just recognition of a new clinical entity. It reaffirmed the dangers of iatrogenic disease and reemphasized the need for proper screening before approval of any drug for treatment.
KeywordsSquamous Epithelium Squamous Metaplasia Urogenital Sinus Clear Cell Adenocarcinoma Epithelial Change
Unable to display preview. Download preview PDF.
- 2.Bulmer D: The development of human vagina. J Anat 1957;93:490–509.Google Scholar
- 4.Brenner P, Sedlis A, Cooperman H: Complete imperforate transverse vaginal septum. Obstet Gynecol 1964;25:135–138.Google Scholar
- 5.Robboy SJ, Noller KL, Kaufman RH, et al: An Atlas of Findings in the Human Female after Intrauterine Exposure to Diethylstilbestrol. NIH Publ no 83–2344. Washington, DC, US Government Printing Office, 1984, 13.Google Scholar
- 6.Robboy SJ: Changes related to prenatal diethylstilbestrol exposure, in Kurman RJ (ed): Blaustein’s Pathology of the Female Genital Tract, ed 3. New York, Springer-Verlag, 1987; page 121.Google Scholar
- 10.Robboy SJ, Noller KL, O’Brien PC, et al: Increased incidence of cervical and vaginal dysplasia in 3,980 diethylstilbestrol exposed young women. JAMA 1984;252:2979.Google Scholar